emeramide

Small moleculeexperimental

BDTH2 (also called BDET and BDETH2; trade names B9, MetX, and OSR#1) is an organosulfur compound that is used as a chelation agent. It is a colourless solid. The molecule consists of two thiol groups and linked via a pair of amide groups. — Wikipedia

Clinical trial activity

4 trials · 4 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Aug 1, 2015 (NCT02486289)

Timeline

2010s

Jan 1, 2015
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Unspecified targetOTHER
Antioxidant and metal chelator
Antioxidant and metal chelator
IronSEQUESTERING AGENT
Iron sequestering agent
MercurySEQUESTERING AGENT
Mercury sequestering agent
Unspecified targetAntioxidant
antioxidant

Chemistry & pharmacology

Loading structure…

SMILES

O=C(NCCS)c1cccc(C(=O)NCCS)c1

Mol. weight: 284.41 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

WikipediaBDTH2 ↗
ChEMBLCHEMBL4297510 ↗

Also known as

emeramide
emeramide
emeramide

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT04183595	Phase 2/Phase 3 (Phase 3)	Feb 1, 2020	Clínica De La Costa Ltda., EmeraMed
NCT04092205	Phase 2	Oct 1, 2019	EmeraMed
NCT03123692	Phase 2	Apr 1, 2017	EmeraMed
NCT02486289	Phase 2	Aug 1, 2015	EmeraMed, FOMAT Medical Research, NBMI Science AB

Showing 4 of 4 trials

Page 1 / 1

Organizations

Research & Development (4)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
EmeraMed	For profit	4	4	2	2015
Clínica De La Costa Ltda.	Academic/Hospital	1	0	1	2020
FOMAT Medical Research	For profit	1	0	1	2015
NBMI Science AB	For profit	1	0	1	2015

4 organizations

Page 1 / 1